Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
Lectura recomendada:
Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy (FIELD Study): A Randomised Controlled Trial
The Lancet, 370(9600):1687-1697
Lectura recomendada:
Treatment of Diabetic Polyneuropathy with the Antioxidant Thioctic Acid (Alpha-Lipoic Acid): A Two Year Multicenter Randomized Double-Blind Placebo Controlled Trial (Aladin II). Alpha Lipoic Acid in Diabetic Neuropathy
Free Radical Research, 31(3):171-179
Lectura recomendada:
Myeloperoxidases and Polycystic Ovary Sindrome
Gynecological Endocrinology, 28(1):3-6
¿Cuál es la vía final de acción de los inhibidores de la dipeptidil peptidasa-4?
Introducción:
La diabetes mellitus tipo 2 es una enfermedad crónica y evolutiva. Los defectos fisiopatogénicos básicos en la evolución y agravamiento de la hiperglucemia son el aumento en la resistencia a la insulina (ligada a la obesidad) y el deterioro en el funcionamiento de las células beta.
Lectura recomendada:
Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
Diabetes Therapy, 3(1):8-8
Lectura recomendada:
The Risk of Overall Mortality in Patients with Type 2 Diabetes Receiving Different Combinations of Sulfonylureas and Metformin: A Retrospective Analysis
Diabetic Medicine, Epub
Lectura recomendada:
Fasting Plasma Glucose 6-12 Weeks after Starting Insulin Glargine Predicts Likelihood of Treatment Success: A Pooled Analysis
Diabetic Medicine, 29(7):933-936
¿Cuál es el mecanismo de acción de la linagliptina en pacientes diabéticos?
Introducción:
La diabetes tipo 2 representa el 90% de los casos de diabetes en los países desarrollados. Es una enfermedad metabólica crónica, causada por una disfunción de las células beta del páncreas, que empeora con el tiempo, sobre una base de resistencia a la insulina en el músculo y el hígado.
Lectura recomendada:
Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin
Clinical Pharmacokinetics, 51(7):411-427
Lectura recomendada:
Influence of the Glucose-Lowering Rate on Left Ventricular Function in Patients with Type 2 Diabetes and Coronary Heart Disease
Journal of Diabetes and its Complications, 26(2):83-88
Lectura recomendada:
Prevalence of Gastroparesis-Related Symptoms in an Unselected Cohort of Patients with Type 1 Diabetes
Journal of Diabetes and its Complications, 26(2):89-93
Lectura recomendada:
Sensitivity of A1C to Diagnose Diabetes is Decreased in High-Risk Older Southeast Asians
Journal of Diabetes and its Complications, 26(2):99-101
Lectura recomendada:
Stratifying Healthcare Costs Using the Diabetes Complication Severity Index
Journal of Diabetes and its Complications, 26(2):107-112
Lectura recomendada:
A Simple Strategy for Screening for Glucose Intolerance, Using Glycated Haemoglobin, in Individuals Admitted with Acute Coronary Syndrome
Diabetic Medicine, 29(7):838-843
Lectura recomendada:
The Cost of Diagnosing Type 2 Diabetes Mellitus By Clinical Opportunistic Screening in General Practice
Diabetic Medicine, 29(7):863-868
Lectura recomendada:
Effect of Screening for Type 2 Diabetes on Population-Level Self Rated Health Otucomes and Measures of Cardiovascullar Risk: 13-Year Follow Up of the Ely Cohort
Diabetic Medicine, 29(7):886-892
Lectura recomendada:
Haemoglobin A1c Cut-Off Point to Identify a High Risk Group of Future Diabetes: Results from the Omiya MA Cohort Study
Diabetic Medicine, 29(7):905-910
Lectura recomendada:
Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988-2002
Annals of Internal Medicine, 144(7):465-474
Lectura recomendada:
Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study
BMJ, 321(7258):405-412